A Randomized Parallel Controlled Study of the Efficacy and Safety of Lornoxicam Versus Etoricoxib after Total Knee Arthroplasty

Abstract

Objectives: The aim of the study was to compare the postoperative analgesic efficacy and safety of lornoxicam versus\retoricoxib for the first 48 hours after surgery.\rMethods: We conducted a prospective randomized controlled study on 110 patients ASAI-II scheduled for TKA under\rspinal anesthesia, who received either lornoxicam 8 mg PO at the end of surgery and a further 8 mg after 12 hours (Lornoxicam\rGroup) or etoricoxib 120 mg at the end of surgery and one placebo pill after 12 hours (Etoricoxib Group). The\rprimary outcome measure was the cumulative dose of morphine administered during the first postoperative 24 and 48\rhours. Secondary outcomes were duration of analgesia and the side effects of the treatment.\rResults: The groups were similar in terms of demographic data. There are no significant differences between groups regarding\rthe morphine consumption at 24 hours (36.2 ± 12 in Lornoxicam group and 34.5 ± 14.1 in Etoricoxib group) and\r48 hours postoperatively (15.6 ± 12.8 in Lornoxicam group and 18 ± 12.3 in Etoricoxib group) or between the duration of\ranalgesia (314.5 ± 70.4 in Lornoxicam group and 320.4 ± 89.2 in Etoricoxib group).\rConclusion: Postoperative use of lornoxicam for 48 hours in the dose of 8 mg PO twice a day in patients undergoing TKA\rhas an analgetic effect comparable to etoricoxib 120 mg, fewer patients experienced adverse symptoms in the etoricoxib\rgroup, but the difference was not statistically significant.